Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cosibelimab, ublituximab, and umbralisib in relapsed/refractory CLL or Richter's Transformation
NCT02535286Phase 1Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- Sep 2015
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cosibelimab-ipdl in chronic lymphocytic leukemia (CLL) and Richter syndrome (RS), sponsored by TG Therapeutics, Inc. Primary endpoint: Adverse Events at 6 months. Started Sep 2015; status: completed.
02
Drugs
cosibelimab-ipdl
03
Conditions
chronic lymphocytic leukemia (CLL)Richter syndrome (RS)
Beyond the preview
Go deeper on NCT02535286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535286.